GHO Capital Invests in FairJourney Biologics

Partners Group Acquires Majority Stake in FairJourney Biologics from GHO Capital

July 1, 2024

Biotechnology

Partners Group has acquired a majority stake in FairJourney Biologics from GHO Capital; GHO will reinvest as a minority investor and founder António Parada remains invested. The transaction will further capitalise FairJourney to expand its antibody discovery and development capabilities, scientific leadership and global footprint.

FairJourney Biologics Acquires Charles River Laboratories' South San Francisco Facility

March 3, 2025

Biotechnology

FairJourney Biologics S.A. has acquired Charles River Laboratories' South San Francisco site (formerly Distributed Bio), including facilities, staff, assets and proprietary antibody libraries and yeast display technology. The acquisition expands FairJourney's antibody discovery and engineering capabilities and establishes a strategic presence in a major U.S. biotech hub to better serve biopharma customers.

GHO Capital and Excellere Partners Invest in Biocare Medical

December 9, 2021

Medical Devices

London-based GHO Capital has invested in Biocare Medical, a California-headquartered developer of immunohistochemistry reagents and diagnostic instrumentation, alongside existing investor Excellere Partners. The capital will be used to accelerate R&D, expand the instrument offering, and support international expansion to capture growing demand for oncology diagnostics.

GHO Capital and Partners Group Invest in Sterling Pharma Solutions

May 25, 2023

Pharmaceuticals

GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.

GHO Capital Acquires Velocity Clinical Research

July 15, 2021

Healthcare Services

Global Healthcare Opportunities (GHO) has acquired Durham-based Velocity Clinical Research from NaviMed Capital and other investors. GHO intends to support Velocity’s roll-up strategy of clinical trial sites, expand its integrated site model (including investment in technology and decentralized trial capabilities) and pursue further geographic expansion, including into Europe.

GHO Capital Invests in RoslinCT

January 11, 2022

Biotechnology

GHO Capital Partners LLP has made a growth equity investment in RoslinCT, a UK-based contract development and manufacturing organisation (CDMO) focused on advanced cell therapies. The capital will support scaling of RoslinCT’s cGMP manufacturing capacity, international customer acquisition and product diversification to drive commercial-scale cell therapy manufacturing.